Perspective Therapeutics Shares Positive 2026 Trial Update – 43% Response Rate in Advanced Neuroendocrine Tumors
New alpha therapy for advanced NETs shows good safety and early tumor shrinkage in ~43% patients, with encouraging results so far.
/ 3 items
#CATX↓
Perspective Therapeutics Stock Plunges 29% Despite 'Remarkable' Safety Data from Cancer Drug Trial
Perspective Therapeutics shares fell 29% to $3.19 after presenting Phase 1/2a trial data for VMT-alpha-NET. Analysts split on outlook despite favorable safety profile and $174M cash position through late 2026.
Perspective Therapeutics: A Buy Rating for the Next-Gen Radiopharmaceutical Leader
BTIG analyst sees Perspective Therapeutics as "next-gen radiopharmaceutical leader" with strong competitive advantages and upcoming catalysts through 2026.